Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.57 |
| ▸ | BCHE | P06276 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | BRD2 | P25440 | 1/20 | 0.54 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854 | 0.92 | BCHE (0.64) | BCHEACHEALB | |
| SCHEMBL13345818 | 0.89 | BRD4 (0.51) | BRD4BCHEACHEALBBRD2 | |
| SCHEMBL10328 | 0.80 | BRD4 (0.51) | BRD4BCHEACHEALBBRD2 | |
| SCHEMBL1391 | 0.80 | BRD4 (0.64) | BRD4BCHEACHEALBBRD2 | |
| SCHEMBL7292545 | 0.80 | PARP1 (0.45) | BRD4BCHEACHEBRD2BRD3 | |
| SCHEMBL3558226 | 0.80 | PTPN1 (0.54) | BRD4BCHEACHEALBBRD2 | |
| SCHEMBL7284779 | 0.79 | MCHR1 (0.49) | BRD4BCHEACHEALBBRD2 | |
| SCHEMBL984 | 0.78 | HTR2A (0.54) | CREBBPHTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL7286561 | 0.77 | PARP1 (0.45) | BRD4BCHEACHEALBBRD2 | |
| SCHEMBL7282759 | 0.76 | PARP10 (0.44) | BRD4BCHEACHEALBBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178937-A1 | PROCESS FOR THE PREPARATION OF ALOSETRON | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2012-07-12 | — | — | US | claimed |
| US-6175014-B1 | SUCH AS 2,3,4,5-TETRAHYDRO-5-METHYL-2-((5-METHYL-1H-IMIDAZOL-4-YL)METHYL)-1H -PYRIDO(4,3-B)INDOL-1-ONE BY REACTION OF CORRESPONDING 2-UNSUBSTITUTED PYRIDO(4,3-B)INDOL-1-ONE AND 4-HYDROXYMETHYL-5-METHYLIMIDAZOLE IN PRESENCE OF STRONG ACID | GLAXO GROUP LIMITED (GB) | 2001-01-16 | — | — | US | claimed |
| EP-0385721-B1 | Process for the preparation of lactam derivatives | GLAXO GROUP LTD (GB) | 1995-01-25 | — | — | EP | claimed |
| EP-0385721-A2 | Process for the preparation of lactam derivatives | GLAXO GROUP LIMITED (GB) | 1990-09-05 | — | — | EP | claimed |
| US-20170107218-A1 | Small Molecule Transcription Modulators of Bromodomains | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-20120178937-A1 | PROCESS FOR THE PREPARATION OF ALOSETRON | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2012-07-12 | — | — | US | disclosed |
| US-20120178937-A1 | PROCESS FOR THE PREPARATION OF ALOSETRON | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2012-07-12 | — | — | US | disclosed |
| US-20100113478-A1 | INDOLONE MODULATORS OF 5-HT3 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113478-A1 | INDOLONE MODULATORS OF 5-HT3 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113478-A1 | INDOLONE MODULATORS OF 5-HT3 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20070059254-A1 | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | TRANSORAL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070059254-A1 | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | TRANSORAL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-5196534-A | PROCESS FOR THE PREPARATION OF LACTAM DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1993-03-23 | — | — | US | disclosed |
| US-5183820-A | Useful for treatment of nausea, vomiting, irritable bowel syndrome and dyspepsia | GLAXO GROUP LIMITED (GB) | 1993-02-02 | — | — | US | disclosed |
| EP-0458624-A1 | Process for the preparation of lactam derivatives | GLAXO GROUP LIMITED (GB) | 1991-11-27 | — | — | EP | disclosed |
| EP-0411901-A2 | Treatment of conditions involving excessive eating | GLAXO GROUP LIMITED (GB) | 1991-02-06 | — | — | EP | disclosed |
| US-4985422-A | TRICYCLIC, IMIDAZOLE SUBSTITUTED, ANTAGONIST OF HYDROXYTRYPTAMINE RECEPTORS, PSYCHOTIC DISORDERS, SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 1991-01-15 | — | — | US | disclosed |
| EP-0385721-A2 | Process for the preparation of lactam derivatives | GLAXO GROUP LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0339959-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-11-02 | — | — | EP | disclosed |
| EP-0306323-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107218-A1 | Small Molecule Transcription Modulators of Bromodomains | NFRKB, NFKBIA, RELA | BRD4 16/4885BCHE 3949/4885ACHE 4601/4885 |
| US-20100113478-A1 | INDOLONE MODULATORS OF 5-HT3 RECEPTOR | HTR3A, HTR3B, HTR3E | BRD4 964/4885BCHE 2269/4885ACHE 512/4885 |
| US-20070059254-A1 | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | HTR5A, HTR1A, HTR3A | BRD4 4363/4885BCHE 441/4885ACHE 302/4885 |
| US-20120178937-A1 | PROCESS FOR THE PREPARATION OF ALOSETRON | CYP4A11, UGT1A4, CYP4F11 | BRD4 4857/4885BCHE 1734/4885ACHE 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.